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Synopsis
Highly Ca2 + permeable receptor potential channel vanilloid type 6 (TRPV6) modulates a variety of biological functions
including calcium-dependent cell growth and apoptosis. So far, the role of TRPV6 in controlling growth of pancreatic
neuroendocrine tumour (NET) cells is unknown. In the present study, we characterize the expression of TRPV6 in
pancreatic BON-1 and QGP-1 NET cells. Furthermore, we evaluate the impact of TRPV6 on intracellular calcium, the
activity of nuclear factor of activated T-cells (NFAT) and proliferation of BON-1 cells. TRPV6 expression was assessed
by real-time PCR and Western blot. TRPV6 mRNA expression and protein production were down-regulated by siRNA.
Changes in intracellular calcium levels were detected by fluorescence calcium imaging (fura-2/AM). NFAT activity was
studied by NFAT reporter assay; cell proliferation by bromodeoxyuridine (BrdU), MTT and propidium iodine staining.
TRPV6 mRNA and protein are present in BON-1 and QGP-1 NET-cells. Down-regulation of TRPV6 attenuates BON-1
cell proliferation. TRPV6 down-regulation is associated with decreased Ca2 + response pattern and reduced NFAT
activity. In conclusion, TRPV6 is expressed in pancreatic NETs and modulates cell proliferation via Ca2 + -dependent
mechanism, which is accompanied by NFAT activation.
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INTRODUCTION
The transient receptor potential (TRP) channel superfamily is
a large group of ion channels composed of seven subgroups
[1]. One of them is the TRP vanilloid family (TRPV), which
consists of six ion channels. TRPVs modulate a variety of cel-
lular processes including hormone secretion, cell migration as
well as growth and apoptosis [1,2]. Numerous studies collect-
ively indicated that these effects are predominantly mediated by
calcium-dependent mechanisms [3–6]. Among all known TRPV
channels, TRPV6 has the highest selectivity for Ca2 + ions [7].
TRPV6 was initially identified in rat duodenum, where it was
implicated in regulating calcium absorption in enterocytes [8].
Later studies showed that TRPV6 is overexpressed in prostate and
breast cancer cells, where it was relevant at stimulating calcium-
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dependently cancer cell proliferation and survival [6,9–11]. Con-
sistently, down-regulation of TRPV6 in prostate cancer cells res-
ulted in decreased cancer cell growth and higher cell death rate
[6,12]. Thus, TRPV6 is currently suggested as a novel target in
prostate cancer therapy. However, in oesophageal squamous cell
carcinoma TRPV6 is down-regulated, which is associated with
a poor survival in male patients [13]. Therefore it appears that
TRPV6 function may be cancer cell type specific.
Little is known about the expression and the role of
TRPV6 in pancreatic neoplasms. TRPV6 is present in pancre-
atic adenocarcinoma and insulinoma cells [14,15]. In insulin-
producing INS-1E cells, TRPV6 down-regulation impairs cell
growth and inhibits insulin mRNA expression [15]. However,
studies addressing the expression and function of TRPV6 in
pancreatic neuroendocrine tumour cells (NETs) are not yet
available.
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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In the present study, we investigated the expression of
TRPV6 in human pancreatic NET cells using well-established
human BON-1 and QGP-1 cell lines [16,17]. Furthermore, we
studied the role of this channel in controlling calcium homoeo-
stasis and proliferation of BON-1 NET cells. Since nuclear factor
of activated T-cells (NFAT) was recently reported to confer pro-
mitogenic role of TRPV6 in prostate cancer cells [6], we also
studied NFAT expression relationship between TRPV6 and NFAT
activity in NET cells.
MATERIALS AND METHODS
Materials
All cell culture media and supplements were purchased from
Biochrom AG. Unless otherwise stated, all other reagents were
from Sigma–Aldrich. Primary rabbit anti-TRPV6 antibody was
purchased from Santa Cruz Biotechnology. Mouse β-actin and
all secondary antibodies were purchased from Sigma–Aldrich.
Cell culture
BON-1 cells were from Dr Courtney M. Townsend, Jr. (University
of Texas Medical Branch, Texas, USA). QGP-1 cells were from
Japanese Health Sciences Foundation, Osaka, Japan. BON-1 cells
were cultured in DMEM/Ham’s F12, QGP-1 cells and LCC-18 in
RPMI medium at 37 ◦C in a humidified atmosphere (5 % CO2,
95 % air). All experiments were performed in medium containing
10 % FBS, 100 kU/l penicillin and 100 mg/l streptomycin.
siRNA transfection
BON-1 cells were transfected with siRNA using HiPerfect re-
agent (Qiagen), according to the manufacturer’s protocol. ON-
TARGETplus SMARTpool of four individual TRPV6 siRNAs
or non-targeting (nt) siRNA were obtained from Thermo Sci-
entific Dharmacon. In brief, before transfection BON-1 cells were
seeded in culture dishes. For determination of cell proliferation
using bromodeoxyuridine (BrdU) and MTT assays, cells were
seeded in 96-well plates (1 × 104 cells/well). For gene expression
analysis, Western blot or cell cycle analysis, cells were seeded
in 6-well plates (1.6 × 105 cells/well). Thereafter nt or TRPV6
siRNA (both at the concentration of 30 nM) were used for fast-
forward transfection. Cells were incubated in the presence of
siRNA for 12 h. Suppression of TRPV6 mRNA expression and
protein production by TRPV6 siRNA was monitored 24, 48
and 72 h after siRNA application.
Real-time PCR
Total RNA was extracted using Tripure reagent (Roche Dia-
gnostics). cDNA was generated from 1 μg of RNA using High
capacity cDNA reverse transcription kit (Life Technologies). Real
time PCR was performed on QuantStudio 12K FlexTM Real-Time
PCR system (Life Technologies). PCR with gene specific primers
(Supplementary Table S1) was performed by using Fast SYBR
Green Master Mix. Relative gene expression was determined by
CT method. GAPDH (glyceraldehyde 3-phosphate dehydro-
genase) was used as reference gene.
Western blot
Proteins were isolated using RIPA buffer (25 mM Tris/HCl
pH 7.6, 150 mM NaCl, 5 mM EDTA, 1 % NP-40 or 1 % Tri-
ton X-100, 1 % sodium deoxycholate, 0.1 % SDS) supplemented
with protease inhibitor cocktail (Roche Diagnostics). Western
blot signals obtained with TRPV6 or β-actin antibodies were
quantified as previously described [18].
Calcium imaging
The intracellular Ca2 + concentration in BON-1 cells was meas-
ured as previously described [4]. In brief, 2 days after nt or
TRPV6 siRNA transfection, cells were pre-incubated with the
fluorescent dye fura-2/AM (2 μM) for 30–40 min at 37 ◦C. The
fura-2 reaction was stopped with a Ringer-like (control) solu-
tion containing (mM): 150 NaCl, 6 CsCl, 1 MgCl2, 10 glucose,
10 HEPES and 1.5 CaCl2, pH of 7.4. Cells were then washed
three times using the same solution to remove cell debris or dead
cells. Fluorescence measurements were performed at room tem-
perature using a microscope (Olympus BW50WI) connected to
a digital imaging system (TILL Photonics) suited for UV excita-
tion. TIDA software was used (HEKA Electronics). Fura-2/AM
fluorescence was alternately excited at wavelengths of 340 and
380 nm and emission was measured at 510 nm. The fluorescence
ratio (f 340 nm/f 380 nm) is a relative index of changes in [Ca2 + ]i
[19]. Prior the experiments, cells were routinely tested to determ-
ine whether the control baseline was constant for 8–20 min (res-
ults not shown). For each measurement, the constant basal levels
of [Ca2 + ]i were confirmed during the first 3 min, followed by
an isoosmotic replacement with a Ca2 + -free Ringer-like solution
(1 mM EGTA). After 3 min, 1.5 mM Ca2 + was added to increase
[Ca2 + ]i. The reversibility of Ca2 + changes is an indicator of cell
viability and functional relevance of the Ca2 + sensing via Ca2 +
channels such as TRPV6 [11,12,20]. Results are presented as
mean traces of f 340/f 380 +− S.E.M.
Determination of NFAT activity
The consequences of TRPV6 down-regulation in BON-1 cells on
NFAT activity were assessed using NFAT reporter assay (Qiagen)
48 h after TRPV6 siRNA transfection, as previously described in
our earlier study [15].
Determination of cell proliferation
Cell proliferation was assessed using a Cell Proliferation ELISA
BrdU colorimetric kit (Roche Diagnostics). In brief, BON-1 cells
were seeded in 96-well plates and transfected with nt or TRPV6
siRNA. After 24, 48, or 72 h, BrdU solution (10 μM) was added
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and cells were incubated for 3 h. The amount of BrdU incor-
poration into DNA was determined according to manufacturer’s
instruction.
Determination of cell viability
To determine viable cells, MTT assay was performed. Cells trans-
fected either with nt or TRPV6 siRNA were analysed using MTT
assay. MTT solution was added to the wells (0.5 mg/ml) 48 h
after transfection of cells either with nt or TRPV6 siRNA. Then,
cells were incubated with MTT for 3 h. Thereafter, medium was
removed from wells and formazan crystals were dissolved in
150 μl DMSO. Absorbance of samples was measured at 570 and
650 nm wave lengths using Synergy 2 Multi-Mode Microplate
Reader (BioTek).
Cell cycle analysis
The consequences of TRPV6 down-regulation in BON-1 cells on
cell cycle were determined using propidium iodide (PI) staining
48 h after siRNA transfection, as described [15].
Statistical analysis
Data were analysed using ANOVA, followed by the Bonferroni
test. P < 0.05 (*), P < 0.01 (**). The Student’s t test (parametric
two-tailed t test) was used for statistical significance determina-
tion between two sets of data. For the evaluation of calcium ima-
ging experiments, significance was determined using Student’s t
test for paired and unpaired data (P-values: two-tailed) provided
they passed a normality test according to Kolmogorov–Smirnov.
If the normality test failed, non-parametric tests were used. Prob-
abilities of P < 0.05 [indicated by asterisks (*) and hash tags (#)]
were considered to be significant. Results are shown as means +−
S.E.M. and were derived in representative experiments performed
in four or three (Western blot) replicates at least.
RESULTS
Expression of TRPV6 in NET cells
We detected TRPV6 mRNA and protein in all three different NET
cell lines; pancreatic BON-1 and QGP-1 cells by real-time PCR
as well as by Western blot (Figures 1A and 1B). Notably, also
the colonic NET cells LCC-18 expressed TRPV6 at mRNA and
protein levels (Figures 1A and 1B). The highest levels of TRPV6
mRNA expression and protein levels were found in BON-1 and
LCC-18 cells. Taking into account the need of experimental sup-
pression of TRPV6 in our study and due to a low expression
of TRPV6 in QGP-1 cells, all subsequent experiments were per-
formed in BON-1 cells. Transfection of BON-1 cells with TRPV6
siRNA for 48 h caused a suppression of mRNA expression by
approximately 65 % (Figure 1C), whereas protein production
decreased by approximately 60 %, as compared with nt siRNA
transfected cells (Figure 1D).
TRPV6 controls Ca2+ regulation in BON-1 cells
To characterize the role of TRPV6 at controlling intracellular
calcium accumulation in pancreatic BON-1 NET cells, we tested
the responses of nt or TRPV6 siRNA transfected cells to rapid
changes of intracellular Ca2 + concentration ([Ca2 + ]i) from a
Ca2 + -free to a 1.5 mM Ca2 + -containing extracellular solution.
In a Ca2 + -free solution, the fluorescence ratio (f 340/f 380) cor-
responding to [Ca2 + ]i decreased from 1.199 +− 0.001 (150 s) to
1.194 +− 0.001 (n = 13; P < 0.005; t = 300 s) in nt siRNA-
transfected BON-1 cells (Figures 2A and 2B). In the presence
of 1.5 mM extracellular Ca2 + , f 340/f 380 increased above the
baseline (1.207 +− 0.005; n = 13; t = 550 s). In cells with down-
regulated TRPV6, no change in f 340/f 380 was detected in the
Ca2 + -free solution until 370 s and only a very slight decrease to
1.199 +− 0.003 was recorded at 400 s (n = 19). After replacement
with the Ca2 + solution, the fluorescence ratio increased back
to the baseline. Thus, changes of [Ca2 + ]i in a Ca2 + -free and a
Ca2 + containing solution were completely inhibited in TRPV6
siRNA-transfected cells as compared with nt transfected BON-1
cells (n = 19; P < 0.01).
TRPV6 modulates pancreatic BON-1 NET cell
proliferation
Next, we examined the effects of TRPV6 down-regulation on
BON-1 cell proliferation. As shown in Figures 3(A) and 3(B),
down-regulation of TRPV6 protein production attenuated BON-
1 cell proliferation. To further confirm the role of TRPV6 in
controlling BON-1 cell growth, we analysed cell cycle in nt and
TRPV6 siRNA-transfected cells. As shown in Figure 3(C), the
number of cells in G1-phase increased after down-regulation of
TRPV6. In contrast, a decreased number of cells in S- and G2-
M phases was detected after experimental reduction of TRPV6
protein production.
Next, we evaluated the effects of TRPV6 down-regulation on
cyclin D1 (CCND1), cyclin D2 (CCND2) and cyclin-dependent
kinase 4 (CDK4). Importantly, these genes are relevant for the
regulation of calcium-dependent cell proliferation [15,21]. We
found that TRPV6 siRNA-transfected cells had lower expression
of CCND1 and CDK4, whereas expression of CCND2 remained
stable as compared with nt siRNA-transfected cells (Figures 3D–
3F). Overall, these results indicate that TRPV6 stimulates BON-1
cell proliferation.
NFAT modulates BON-1 cell growth and viability
Previous studies indicated that TRPV6 modulates proliferation
of LNCaP human prostate adenocarcinoma or INS-1E cells via
NFAT-dependent mechanisms [6,15]. As demonstrated in Fig-
ure 4(A), BON-1 and LCC-18 cells express all calcium sensit-
ive NFAT isoforms. Since the role of NFAT at controlling NET
cell proliferation is unknown, we assessed whether two differ-
ent well-characterized pharmacological inhibitors of NFAT activ-
ity (cyclosporine A and FK506) [22] can influence BON-1 cell
growth. As expected, both cyclosporine as well as FK506 at-
tenuated NFAT activity (Figure 4B). Furthermore, both NFAT
inhibitors reduced BON-1 cell proliferation in a dose-dependent
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Figure 1 TRPV6 mRNA expression and protein production in NET cells
(A) Real time PCR detection of TRPV6 mRNA expression in QGP-1, BON-1 and LCC-18 cells. (B) Western blot detection of
TRPV6 protein in BON-1, QGP-1 and LCC-18 cells. (C) Suppression of TRPV6 mRNA expression in BON-1 cells transfected
with siRNA for 48 h in comparison with BON-1 cells transfected with non-targeting construct (nt). (D) Suppression of TRPV6
protein production in BON-1 cells 48 h after siRNA transfection in comparison with nt BON-1 cells. Results are the mean
+− S.E.M., obtained from at least n = 3.
fashion (Figures 4C–4F). In summary, these data show that NFAT
stimulates BON-1 cell growth.
TRPV6 modulates NFAT activity but not NFAT
expression
TRPV6 can modulate NFAT activity in Caco-2 (human epithelial
colorectal adenocarcinoma), LNCaP and INS-1E cells [6,15,23].
Therefore, we examined the effect of TRPV6 down-regulation
on NFAT activity in BON-1 cells. As a result, TRPV6 siRNA-
transfected BON-1 cells had decreased NFAT activity as com-
pared with nt siRNA-transfected cells (Figure 5A). In contrast,
expression of NFATs was not affected by TRPV6 siRNA down-
regulation (Figure 5B). To confirm whether TRPV6 modulates
BON-1 cell proliferation via NFAT-dependent mechanism, we
investigated whether pharmacological blockade of NFAT activ-
ity in cells with down-regulated TRPV6 protein production has
an additive effect on inhibition of BON-1 cell proliferation. FK
506 failed to further suppress BON-1 proliferation in cells with
down-regulated TRPV6. These results demonstrate that TRPV6
modulates NET cell proliferation by affecting NFAT activity.
DISCUSSION
In the present study, we detected the presence of TRPV6 channel
in human pancreatic BON-1 NET cells for the first time. Further-
more, we demonstrated that TRPV6 controls calcium homoeo-
stasis as well as proliferation of pancreatic BON-1 NET cells.
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Figure 2 Effect of TRPV6 down-regulation on Ca2+ regulation in
BON-1 cells
(A) Measurement of intracellular Ca2 + concentration in cells transfec-
ted either with TRPV6 or nt siRNA. The basal Ca2 + level was measured
during the first 200 s followed by Ca2 + reduction (left arrow) under
Ca2 + -free condition and a Ca2 + increase after 1.5 mM Ca2 + exposure
at 380 s. (right arrow). Intracellular Ca2 + increases above the base
line (dashed line) in nt siRNA-transfected cells could be detected after
re-addition of extracellular Ca2 + (open circles) (n= 13). In contrast, this
effect could be clearly suppressed in TRPV6 siRNA-transfected BON-1
cells (filled circles) (n = 19). Changes in cytosolic free Ca2 + are depic-
ted as the ratio of the fluorescence induced by excitation wavelength of
340 and 380 nm by the equation of Grynkiewicz et al. [19]. (B) Sum-
mary of the experiments with nt and TRPV6 siRNA-transfected BON-1
cells. Statistical evaluation of [Ca2 + ]i was performed after 300 s (light
grey bars) and 600 s (dark grey bars).
Recently, we and others showed that pancreatic NETs express
several members TRP channels such as TRPV1 as well as TRPM8
channels [4,24]. Both TRPs regulate intracellular calcium con-
centration and various secretory activities of NET cells.
In the present study, we specifically showed that different
human pancreatic NET cell lines (BON-1, QGP-1) as well as
colonic LCC18 NET cells express TRPV6 at mRNA and protein
levels, however at striking differences (Figure 1). Among pan-
creatic NET cell lines BON-1 showed a high TRPV6 expression,
whereas QGP-1 poorly expressed TRPV6. Using siRNA, we also
showed that suppression of TRPV6 protein production in BON-
1 cells is associated with a decreased calcium response patterns,
which is in accordance with previously published protocol for de-
tection of TRPV6 channel activity [6] (Figure 2). In our previous
study using NET BON-1 cells and the same protocol, we detec-
ted similar Ca2 + response patterns [4]. These response patterns
were clearly suppressed by different TRP channel blockers indic-
ating TRP channel activity in BON-1 cells [4]. Finally, the link
between TRPV6 and calcium homoeostasis is in agreement with
previous studies performed in other neoplasms such as breast,
prostate cancer cells or insulinoma cells [6,15,25].
Several studies showed that TRPV6 modulates cell prolifer-
ation via Ca2 + -dependent mechanism. In the present study, we
found that suppression of TRPV6 protein production decreases
BON-1 cell growth by approximately 30 % and leads to declined
CCND1 and CDK4 expression, without affecting CCND2 (Fig-
ure 3). Both CCND1 and CDK4 are important for cell cycle
regulation [15,21,26]. Importantly, we assessed NET cell pro-
liferation in the presence of 10 % serum (FCS) to better reflect
the physiological conditions. Therefore, our experimental data
strongly suggest that TRPV6 is a potent regulator of BON-1 cells
proliferation, even in the presence of serum.
There is convincing evidence indicating that TRPV6 modu-
lates NFAT activity [6,15]. Transcription factors of the NFAT
family (NFATs), initially described in immune cells, are re-
quired for calcium-dependent immune responses [27]. Moreover,
NFATs were also detected in other tissues including heart, brain
and pancreas [21,27]. Although it was already reported that
NFAT expression and activity are required for pancreatic β or
insulinoma cells growth [15,21], nothing is known neither about
the expression, nor potential roles of NFATs in controlling NETs
growth, and death. This transcription factor family is composed
of five members termed as NFATc1, NFATc2, NFATc3, NFATc4
and NFAT5. First four members (NFATc1-NFATc4) are modu-
lated via calcium signalling [28]. Therefore, we initially invest-
igated whether calcium-regulated NFATs (NFATc1-NFATc4) are
expressed in our NET cells, at all. As a result, we identified all
of them in tested NET cell lines (Figure 4). Notably, previous
studies showed that NFAT pathway confers promitogenic prop-
erties of TRPV6 in LNCaP or INS-1E cells [6,15]. In INS-1E
cells, suppression of TRPV6 protein production or NFAT activ-
ity was associated with reduced expression of Ca2 + -regulated
genes, such as CCND2 and CDK4. Concordantly, it was earlier
demonstrated that down-regulation of TRPV6 in INS-1E cells
was accompanied by attenuated cell proliferation and viability
[15]. In the present study, we assessed the consequences of phar-
macological suppression of NFAT activity in regulating BON-1
cells growth. Both FK506 and cyclosporine A (CsA) lowered
NFAT activity (Figure 4). Furthermore, BON-1 cell proliferation
was reduced in response to cyclosporine or FK506 treatment.
Nevertheless, it must be pointed out that cyclosporine exerts other
activities such as inhibition of mitochondrial permeability trans-
ition pore opening [29].
This data suggest that cyclosporine may also modulate cell
proliferation independently of NFAT inhibition, e.g. by affect-
ing mitochondrial functions. However, a vast majority of stud-
ies showed that inhibition of mitochondrial permeability trans-
ition pore opening is relevant in the context of CsA-induced
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Figure 3 Effects of TRPV6 down-regulation on BON-1 cells proliferation and cell cycle
(A) BON-1 cell proliferation assed 24, 48 and 72 h after transfection with siRNA. (B) The number of viable BON-1 cells
studied 48 h after transfection with siRNA using MTT assay. (C) BON-1 cell cycle analysis 48 h after siRNA transfection.
(D–F) Expression of CCND1, CCND2 and CDK4 in cells transfected with siRNA for 48 h. Results are the mean +− S.E.M.,
obtained from at least n = 4.
cytoprotection. For instance, CsA can protect β-cells from death
induced by high glucose or promote cardioprotection by inhibit-
ing mitochondrial permeability transition [30,31]. CsA can also
increase retinal ganglion cell survival by preventing mitochon-
drial alteration in ischemic injury [32].
Additional novel finding in our study is that NFAT activity de-
creased after down-regulation of TRPV6 protein in BON-1 cells
(Figure 5). This corresponds to observations in a prostate cancer
LNCaP cell line or insulin secreting INS-1E cell line [6,15]. Im-
portantly, we observed that pharmacological blockade of NFAT
in cells with down-regulated TRPV6 protein had no additional
antiproliferative activity in BON-1 cells. NFAT activity is pre-
sumably modulated by changes in intracellular calcium levels
[33]. There is strong evidence that extracellular Ca2 + ions are
required to activate NFAT. For example depletion of extracellu-
lar Ca2 + causes a suppression of transcription activity of NFAT
in neuronal PC12 cells [34]. Thus, since we observed that cells
with TRPV6 down-regulation had a low NFAT activity, these
results indicate that TRPV6 controls intracellular Ca2 + levels by
modulating calcium transport from extracellular environment.
The relationship between TRPV6, intracellular Ca2 + levels and
NFAT signalling is well-supported by literature [6,15,23].
Overall, these data indicate that the active NFAT is essential to
maintain the growth of NETs cells and allows us to suggest that
TRPV6 may control BON-1 cells growth via NFAT-dependent
mechanism.
Overall, our results show a functional link between TRPV6 and
NFAT activity and emphasize the relevance of this interaction at
maintaining BON-1 NET cell growth. One of the limitations of
our study is the exclusive use of NET cell lines instead of primary
NET cells. Regarding other Ca2 + channels, however, we could
show similar electrophysiological characteristics between several
NET cell lines and corresponding primary NET cells [4,24,35].
Therefore, we suggest that particularly the aforementioned
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Figure 4 Effects of NFAT suppression on BON-1 cells proliferation
(A) Expression of NFATs in BON-1 and LCC-18 cells. (B) NFAT activity in BON-1 cells treated with 10 μM FK506 or 10 μM
CsA for 24 h. BON-1 cell proliferation treated with FK506 (C) or CsA (D) for 24 h. The number of viable BON-1 cells assed
after 24 incubation in the presence of FK506 (E) or CsA (F). Results are the mean +− S.E.M., obtained from at least n = 4.
BON-1 cell line is a valid surrogate NET cell model to character-
ize Ca2 + channels as well as TRPV6. Further studies are required
to confirm the role of TRPV6 at modulating calcium-dependent
cell growth. Furthermore, despite conduction of our experiments
in the presence of 10 % serum, our study fails to identify the
endogenous stimuli of TRPV6 activity in NETs. However, this is
not the focus of our study.
Moreover, it remains a matter of debate whether TRPV6 is
constitutively active at physiological conditions. Several studies
suggested that TRPV6 is characterized by constitutively activ-
ated Ca2 + permeability at physiological membrane potentials
[36]. Other studies indicated that TRPV6 activity is modulated
by changes in intracellular and extracellular Ca2 + concentra-
tions or plasma membrane depolarization (extensively studied
by Bodding et al. [37]). Notably, there is evidence indicating
that TRPV6-mediated calcium influx can be potentiated by 17β-
oestradiol [38]. Importantly, 17β-oestradiol was demonstrated
to increase breast cancer cell proliferation [39] which show ex-
tremely high density of TRPV6 expression [11]. Therefore, it is
possible that 17β-oestradiol may play a role in regulating cell
growth, also in pancreatic NET cells.
Further studies using primary NETs are required to evaluate
the potential clinical relevance of our results. For example, a link
between TRPV6 and various growth factors relevant in NETs
proliferation should be assessed in the future.
In summary, our study shows for the first time that TRPV6 is
expressed in pancreatic NETs, where it modulates intracellular
calcium concentration. Furthermore, we show that suppression of
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Figure 5 NFAT activity and expression in BON-1 cells with down-
regulated TRPV6
NFAT activity (A) and expression (B) evaluated in cells transfected either
with nt (white bars) or TRPV6 siRNA (grey bars) for 48 h. (C) Effects of
24 h treatment with FK506 on BON-1 cells transfected with nt (white
bars) or TRPV6 siRNA (grey bars) for 48 h. Results are the mean +−
S.E.M. (n = 4).
TRPV6 protein production is associated with impaired pancreatic
NET cell growth.
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